Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1
Thus, romosozumab might be a specific treatment for these patients. However, further studies are needed with larger patient cohorts and in particular with regard to biallelic loss-of-function variants in the LRP 5/6 or WNT1 gene.
Authors
- Uwe Kornak (ORCID: https://orcid.org/0000-0002-4582-9838)
- Florian Barvencik (ORCID: https://orcid.org/0000-0002-0200-8431)
- Thorsten Schinke (ORCID: https://orcid.org/0000-0002-8576-0177)
- Ralf Oheim (ORCID: https://orcid.org/0000-0001-9449-5013)
- N Dehne
- M Amling
- F N von Brackel
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- Osteoporosis International
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s00198-026-07932-8
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft